ClinicalTrials.gg
Not yet recruitingNCT06980922Updated May 20, 2025

The Efficacy and Safety of Guilu Erxian Jiao in the Treatment of Intradialytic Hypotension

A Phase 2 interventional study of Guilu Erxian Jiao in Intradialytic Hypotension, End-Stage Renal Disease and Hemodialysis, sponsored by Chang Gung Memorial Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Chang Gung Memorial Hospital · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 70 studies in Kidney Failure, Chronic with a site in Taiwan — 11 open to participants now, 13 under way, 2 of them phase 3. Kidney Failure, Chronic · Taiwan.

Planned enrollment
45th of 52
34 · median 80
Started
2025
with 3 others
Phase 2
4 of 70
2 open now
Primary completion
2027-05
later than 6 of 12 live
Registered
63rd of 70
by date
Lead sponsor
6 of 70
Chang Gung Memorial Hospital

Among the 70 studies in Kidney Failure, Chronic with a site in Taiwan, this one is the 45th largest by planned enrollment of the 52 interventional ones that give a count, is one of 4 that started in 2025, is one of 4 in phase 2, reaches primary completion later than 6 of the 12 other live ones, and was the 63rd registered.

Kidney Failure, Chronic

2,115 studies on the registry are indexed under Kidney Failure, Chronic; 277 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

11 of the 70 studies in Kidney Failure, Chronic with a site in Taiwan are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 170 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Kidney Failure, Chronic with a site in Taiwan, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if Guilu Erxian Jiao, a traditional Chinese herbal medicine, can help manage intradialytic hypotension (IDH), a drop in blood pressure that occurs during hemodialysis in adults. The main questions it aims to answer are:

  1. Does Guilu Erxian Jiao reduce the frequency and severity of low blood pressure during dialysis?
  2. Is Guilu Erxian Jiao safe to use in patients receiving hemodialysis?

Researchers will compare standard care plus Guilu ErXian Jiao to standard care alone to see if Guilu Erxian Jiao improves blood pressure stability during dialysis.

Participants will:

  1. Take Guilu Erxian Jiao once daily in addition to standard care, or receive standard care alone, for 4 weeks, then switch treatments after a 4-week washout period (crossover design).
  2. Undergo follow-up assessments at weeks 2 and 4 after each treatment phase.
  3. Have their blood pressure monitored before, during (hourly), and after each dialysis session.
  4. Report dialysis-related symptoms such as dizziness and fatigue.
  5. Receive routine laboratory tests and safety monitoring throughout the study.
Read the detailed description
  1. Clinical Background and Study Rationale

    Intradialytic hypotension (IDH) is defined as a decrease in systolic blood pressure of more than 20 mmHg or a drop of more than 10 mmHg in mean arterial pressure during hemodialysis, often accompanied by symptoms such as dizziness, nausea, or cramps. The incidence of IDH among dialysis patients is approximately 5% to 30%. Risk factors include advanced age, diabetes, female sex, and high body mass index. IDH can cause premature termination of dialysis sessions, resulting in decreased uremic toxin clearance and increased long-term mortality and complications. Severe IDH may lead to bowel ischemia, stroke, or myocardial infarction.

    Common management strategies for IDH include adjusting the dialysis rate, lowering dialysate temperature, avoiding eating during dialysis, and strict sodium intake control. In cases of frequent IDH episodes, drugs such as Midodrine or Vasopressin may be used. However, oral Midodrine can cause side effects such as urinary retention, paresthesia, and pruritus. Its long-term safety in dialysis patients is yet to be confirmed.

    According to Traditional Chinese Medicine (TCM), IDH results from spleen and kidney Qi deficiency, requiring tonification of these organs. Guilu Erxian Jiao (GLJ) is a classical formula composed of Testudinis Carapax, Cervi Cornu, Lycii Fructus, and Ginseng Radix, commonly used to treat Qi deficiency and hypotension. Clinical experience suggests potential efficacy in reducing IDH frequency, but large-scale trials are lacking.

    This trial aims to evaluate the efficacy and safety of GLJ in treating IDH in patients undergoing hemodialysis.

  2. Study Design and Methods

    This is a randomized, open-label, crossover clinical trial enrolling 34 patients aged over 18 years who receive thrice-weekly hemodialysis for four hours per session and have a history of IDH. Patients are recruited from nephrology and TCM outpatient clinics and the dialysis unit of Keelung Chang Gung Memorial Hospital.

    Participants will be randomized 1:1 into two groups. Randomization will be performed using a computer-generated random sequence. Participants will be assigned to groups according to sealed envelopes that indicate their allocation. Group A receives GLJ plus conventional treatment for four weeks, followed by a four-week washout period, then four weeks of conventional treatment alone. Group B follows the reverse sequence.

    GLJ (Guilu Erxian Jiao) is administered once daily before meals at a dose of 4 grams for four weeks. The preparation used is Jipin Guilu Baishen San produced by Sun Ten Pharmaceutical Co., Ltd. (License number: 016966).

    Data collected include demographic information, medical history, allergy history, family history, medication history, and socioeconomic status. Evaluations include blood pressure measurements before, during, and after dialysis; frequency of IDH episodes; symptoms such as dizziness and fatigue (via VAS score); laboratory parameters (Na, K, Ca, P, BUN, Cr); and adverse events.

    Follow-up evaluations occur at weeks 2 and 4 after each treatment phase. Each assessment takes approximately 30 minutes.

  3. Participant Safety, Compensation, and Withdrawal Rights

    Guilu Erxian Jiao is generally well tolerated. Reported side effects in prior studies include mild dry mouth and constipation. During the study, blood and biochemical parameters will be regularly monitored to detect any possible adverse effects.

    If allergic reactions or serious adverse events occur during the trial, the participant will be withdrawn from the study and provided with appropriate medical evaluation and care.

    Participants may voluntarily withdraw from the study at any time without providing a reason and without any impact on their standard medical care. Likewise, the principal investigator reserves the right to terminate a participant's involvement or discontinue the trial at any time for safety or administrative reasons.

    In case of adverse events or injuries resulting from participation in this study, and if they occur in accordance with the approved protocol, the institution and the principal investigator will be legally responsible for providing necessary compensation. However, no compensation will be provided for anticipated side effects explicitly stated in the study protocol. In addition to compensation, the hospital will also provide professional medical care and consultation at no cost for treating the injury.

  4. Data Privacy and Confidentiality

    Participant identities will be anonymized using unique study codes, and no personally identifiable information (e.g., name, medical record number) will appear in the case reports or publications. Study data will be securely stored in locked cabinets and password-protected, encrypted folders for at least two years after the end of the study. Only the principal investigator, authorized research team members, auditors, the ethics committee, and regulatory authorities will have access to the original data for monitoring and auditing purposes. The research team is committed to maintaining confidentiality and protecting participants' privacy throughout the study.

  5. Statistical Analysis

    Sample size calculation was based on previous studies with a significance level of 0.05 and power of 0.99, resulting in a required 28 participants; with an estimated 20% dropout rate, 34 participants will be enrolled.

    Statistical analyses include Student's t-test, Chi-square test, ANOVA, and paired t-tests as appropriate. Non-parametric tests will be used if data are not normally distributed. All efficacy analyses will be performed using the intention-to-treat (ITT) principle, including all randomized participants who received at least one dose of study intervention. A one-sided alpha of 0.05 defines statistical significance.

  6. IRB Review and Approval This study has been reviewed and approved by the Institutional Review Board of Chang Gung Memorial Hospital, Keelung Branch (IRB No. 2402010026, Protocol Version 5, approved on 2025/03/12).
03

Conditions studied

  • Intradialytic Hypotension
  • End-Stage Renal Disease
  • Hemodialysis

Keywords

  • Intradialytic Hypotension
  • Hemodialysis
  • Traditional Chinese Medicine
  • Herbal Medicine
  • Guilu Erxian Jiao
  • End-Stage Renal Disease
  • Randomized Controlled Trial
  • Kidney Disease
  • Dialysis Complications
  • Blood Pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Undergoing maintenance hemodialysis three times per week, 4 hours per session
  • History of intradialytic hypotension (IDH)
  • Willing and able to provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women
  • Severe comorbid illness, such as cancer, stroke, or liver cirrhosis
  • Inability to comply with study medication regimen
  • Regular use of antihypertensive medication
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Group A

    Participants in Group A will receive Guilu Erxian Jiao (GLJ) plus usual care for 4 weeks, followed by a 4-week washout period, then 4 weeks of usual care alone.

    Drug: Guilu Erxian Jiao

  • Active comparator
    Group B

    Participants in Group B will receive usual care alone for 4 weeks, followed by a 4-week washout period, then 4 weeks of Guilu Erxian Jiao (GLJ) plus usual care.

    Drug: Guilu Erxian Jiao

Interventions

  • DrugGuilu Erxian Jiao

    A traditional Chinese herbal formula composed of Testudinis Carapax, Cervi Cornu, Lycii Fructus, and Ginseng Radix, manufactured by Sun Ten Pharmaceutical Co., Ltd. (License No. 016966). Administered orally at 4 grams per day before meals for 4 weeks.

    Also known as: Jipin Guilu Baishen San

06

What researchers measure

Primary outcomes

  1. Frequency of Intradialytic Hypotension Episodes

    Number of intradialytic hypotension (IDH) episodes, defined as a drop in systolic blood pressure \>20 mmHg or mean arterial pressure (MAP) \>10 mmHg, recorded during each dialysis session.

    Time frame: From baseline through the entire 16-week crossover study, including each 4-week treatment phase and follow-up assessments conducted at 2 and 4 weeks after each treatment phase

Secondary outcomes

  1. Change in Blood Pressure Before, During, and After Dialysis

    Systolic and diastolic blood pressure measurements are collected before dialysis, hourly during dialysis, and after each dialysis session, then averaged for comparison between treatment phases.

    Time frame: From baseline through the entire 16-week crossover study, including each 4-week treatment phase and follow-up assessments conducted at 2 and 4 weeks after each treatment phase

  2. Visual Analogue Scale (VAS) Scores for Dialysis-Related Clinical Symptoms

    Patient-reported dialysis-related clinical symptoms, such as dizziness and fatigue, are measured using a 0-10 Visual Analogue Scale (VAS) at designated time points throughout the study.

    Time frame: Assessments are conducted after each dialysis session throughout the 16-week crossover study, including each 4-week treatment phase and follow-up assessments at 2 and 4 weeks after each treatment phase, starting from baseline

  3. Changes in Laboratory Parameters (Na, K, Ca, P, BUN, Cr)

    Serum levels of sodium, potassium, calcium, phosphate, blood urea nitrogen, and creatinine measured at specified time points to assess biochemical changes.

    Time frame: At baseline and at week 4, 8, 12, and 16 of the study

  4. Adverse Events Related to Guilu Erxian Jiao

    All adverse events reported by participants, including dry mouth, constipation, and other symptoms, recorded and monitored throughout the study.

    Time frame: Throughout the entire 16-week study period

  5. Dialysis Nurse Interventions for IDH

    Clinical interventions performed by dialysis nurses in response to intradialytic hypotension, including ultrafiltration adjustment, lowering dialysate temperature, and physician-directed interventions such as fluid administration or early termination of dialysis, as well as other standard nursing responses to IDH, will be recorded at each dialysis session during all study phases.

    Time frame: During each dialysis session throughout the 16-week crossover study, including each 4-week treatment phase, and follow-up assessments conducted at 2 and 4 weeks after each treatment phase

07

Study locations

1 site
08

References and documents

Publications

  • Brunelli SM, Cohen DE, Marlowe G, Van Wyck D. The Impact of Midodrine on Outcomes in Patients with Intradialytic Hypotension. Am J Nephrol. 2018;48(5):381-388. doi: 10.1159/000494806. Epub 2018 Nov 13. PubMed 30423552 ↗
  • Jindal K, Chan CT, Deziel C, Hirsch D, Soroka SD, Tonelli M, Culleton BF; Canadian Society of Nephrology Committee for Clinical Practice Guidelines. Hemodialysis clinical practice guidelines for the Canadian Society of Nephrology. J Am Soc Nephrol. 2006 Mar;17(3 Suppl 1):S1-27. doi: 10.1681/ASN.2005121372. No abstract available. PubMed 16497879 ↗
  • Flythe JE, Xue H, Lynch KE, Curhan GC, Brunelli SM. Association of mortality risk with various definitions of intradialytic hypotension. J Am Soc Nephrol. 2015 Mar;26(3):724-34. doi: 10.1681/ASN.2014020222. Epub 2014 Sep 30. PubMed 25270068 ↗
  • Morfin JA, Fluck RJ, Weinhandl ED, Kansal S, McCullough PA, Komenda P. Intensive Hemodialysis and Treatment Complications and Tolerability. Am J Kidney Dis. 2016 Nov;68(5S1):S43-S50. doi: 10.1053/j.ajkd.2016.05.021. PubMed 27772642 ↗
  • Flythe JE, Inrig JK, Shafi T, Chang TI, Cape K, Dinesh K, Kunaparaju S, Brunelli SM. Association of intradialytic blood pressure variability with increased all-cause and cardiovascular mortality in patients treated with long-term hemodialysis. Am J Kidney Dis. 2013 Jun;61(6):966-74. doi: 10.1053/j.ajkd.2012.12.023. Epub 2013 Mar 6. PubMed 23474007 ↗
  • Tattersall J, Martin-Malo A, Pedrini L, Basci A, Canaud B, Fouque D, Haage P, Konner K, Kooman J, Pizzarelli F, Tordoir J, Vennegoor M, Wanner C, ter Wee P, Vanholder R. EBPG guideline on dialysis strategies. Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii5-21. doi: 10.1093/ndt/gfm022. No abstract available. PubMed 17507427 ↗
  • Mo Y, Liu X, Qin X, Huang J, He Z, Lin J, Hu Q, Cai Y, Liu Z, Wang L. Shenfu injection for intradialytic hypotension: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2014;2014:279853. doi: 10.1155/2014/279853. Epub 2014 Dec 22. PubMed 25587340 ↗
  • Sands JJ, Usvyat LA, Sullivan T, Segal JH, Zabetakis P, Kotanko P, Maddux FW, Diaz-Buxo JA. Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome. Hemodial Int. 2014 Apr;18(2):415-22. doi: 10.1111/hdi.12138. Epub 2014 Jan 27. PubMed 24467830 ↗
  • Kooman J, Basci A, Pizzarelli F, Canaud B, Haage P, Fouque D, Konner K, Martin-Malo A, Pedrini L, Tattersall J, Tordoir J, Vennegoor M, Wanner C, ter Wee P, Vanholder R. EBPG guideline on haemodynamic instability. Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii22-44. doi: 10.1093/ndt/gfm019. No abstract available. PubMed 17507425 ↗

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to privacy protection concerns and no current plan for secondary data use.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2025; primary completion for May 2027, 23 months later.

Of 41 non-industry phase 2 interventional studies under Kidney Failure, Chronic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 52. This study's planned 23 months is below that.

Counting every sponsor, half of 67 studies reached it within 32 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 20, 2025
StartEst.
Jun 1, 2025
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2028
Last update
May 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06980922
Responsible party
Sponsor
First posted
May 20, 2025
Start date
Jun 1, 2025 (estimated)
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
May 20, 2025

Study contacts

Huan-Hsuan Hsu, M.D.
Contact
10356017a@cgmh.org.tw
+886-2-24313131 ext. 2677
Chun-Jung Lin, M.D.
Contact
s81101911@cgmh.org.tw
+886-2-24313131 ext. 2677
Huan-Hsuan Hsu, M.D.
principal investigator · Department of Chinese Medicine, Keelung Chang Gung Memorial Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion